---
id: 203
title: Acute Bacterial Meningitis - Empiric Treatment
category: clinical_syndromes
subcategory: central_nervous_system
tags: [meningitis, bacterial-meningitis, dexamethasone, lumbar-puncture, vancomycin, ceftriaxone]
difficulty: high
---

## Question

How is bacterial meningitis managed empirically? Use **"Ceftriaxone + Vanc + Dex, Add Ampicillin if >50y or Immunocompromised (Listeria)"** framework.

## Answer

### **Empiric Antibiotics (Start Immediately):**

**Do NOT Delay for LP** (if CT needed or LP delayed)

**Age <50 Years, Immunocompetent:**
- **Ceftriaxone 2g IV q12h** + **vancomycin 15-20 mg/kg IV q8-12h**

**Age ≥50 Years OR Immunocompromised:**
- **Ceftriaxone 2g IV q12h** + **vancomycin 15-20 mg/kg IV q8-12h** + **ampicillin 2g IV q4h**
- **Ampicillin covers *Listeria monocytogenes***

**Neurosurgery / Head Trauma / CSF Shunt:**
- **Vancomycin** + **cefepime 2g IV q8h** OR **meropenem 2g IV q8h**
- **Covers *Pseudomonas*, resistant Gram-negatives**

**Dexamethasone (Adjunctive):**
- **10mg IV q6h × 4 days**
- **Give with or before first antibiotic dose**
- **Reduces mortality/neurologic sequelae** in *S. pneumoniae* meningitis

### **Pathogen-Directed Therapy:**

***Streptococcus pneumoniae* (Most Common Adult):**

**PCN-Susceptible (MIC <0.06):**
- **Penicillin G 4 million units IV q4h × 10-14 days**

**PCN-Intermediate/Resistant OR Unknown:**
- **Ceftriaxone 2g IV q12h** + **vancomycin 15-20 mg/kg IV q8-12h × 10-14 days**
- **Switch to ceftriaxone alone** if susceptible (MIC <0.5 for ceftriaxone)

***Neisseria meningitidis*:**
- **Penicillin G 4 million units IV q4h OR ceftriaxone 2g IV q12-24h × 7 days**

***Listeria monocytogenes* (>50y, Immunocompromised):**
- **Ampicillin 2g IV q4h × ≥21 days**
- **+ Gentamicin 5-7 mg/kg IV daily × first 7-14 days** (synergy)
- **TMP-SMX alternative** if PCN allergy: 5 mg/kg (TMP component) IV q8h

***Haemophilus influenzae*:**
- **Ceftriaxone 2g IV q12h × 7-10 days**

***Streptococcus agalactiae* (Group B Strep, Neonates/Elderly):**
- **Penicillin G 4 million units IV q4h OR ampicillin 2g IV q4h × 14-21 days**

**Gram-Negative Rods (Post-Neurosurgery):**
- **Cefepime 2g IV q8h** OR **meropenem 2g IV q8h × 21 days**

### **Dexamethasone Use:**

**Benefits:**
- **Reduces mortality** (*S. pneumoniae* meningitis)
- **Reduces neurologic sequelae** (hearing loss, cognitive impairment)

**Dosing:**
- **10mg IV q6h × 4 days** (start with or before antibiotics)

**Controversies:**
- **May reduce CSF antibiotic penetration** (vancomycin, especially)
- **Give first dose before/with antibiotics** (maximal benefit if started early)
- **Can discontinue** if non-*S. pneumoniae* confirmed (e.g., *N. meningitidis*)

### **Lumbar Puncture:**

**When to Delay LP (Get CT First):**
- **Immunocompromised** (HIV, transplant)
- **History of CNS disease** (mass lesion, stroke, infection)
- **New seizure** (within 1 week)
- **Papilledema, focal neurologic deficits**
- **Altered consciousness** (GCS ≤10)

**Give Antibiotics BEFORE CT/LP** (if delay expected)

**CSF Findings:**
- **WBC:** 100-10,000+ (>1000 typical), >80% PMNs
- **Protein:** ↑↑ (100-500+ mg/dL)
- **Glucose:** ↓↓ (<40 mg/dL, CSF:serum <0.4)
- **Gram stain:** Positive 60-90%
- **Opening pressure:** Elevated (>25 cm H₂O)

### **Complications:**

**Acute:**
- **Seizures** (20-30%)
- **Increased ICP** (cerebral edema, hydrocephalus)
- **Stroke** (vasculitis, thrombosis)
- **SIADH** (hyponatremia)

**Long-Term:**
- **Hearing loss** (10-30%, especially *S. pneumoniae*)
- **Cognitive impairment**
- **Focal neurologic deficits**

**Mortality:**
- ***S. pneumoniae*:** 15-20%
- ***N. meningitidis*:** 5-10%
- ***Listeria*:** 20-30%

### **Chemoprophylaxis (Close Contacts):**

***N. meningitidis*:**
- **Rifampin 600mg PO BID × 2 days**
- OR **ciprofloxacin 500mg PO × 1**
- OR **ceftriaxone 250mg IM × 1**
- **Indications:** Household contacts, direct exposure to oral secretions

***H. influenzae* (If Unvaccinated Child <4y in Household):**
- **Rifampin 20 mg/kg (max 600mg) PO daily × 4 days** (all household contacts)

### **Repeat LP:**

**Indications:**
- **Clinical failure** (persistent fever, worsening neurologic status after 48-72h)
- ***S. pneumoniae* with high-level resistance** (MIC ≥2)

**Not Routinely Needed** if clinical improvement

## Keys Points

### **Empiric = Ceftriaxone + Vancomycin:**
- **Covers *S. pneumoniae*** (including resistant strains)
- **Add ampicillin** if age ≥50 or immunocompromised (*Listeria*)

### **Dexamethasone Before/With Antibiotics:**
- **10mg IV q6h × 4 days**
- **Reduces mortality** (*S. pneumoniae*)
- **Must give early** (with or before first antibiotic)

### **Do NOT Delay Antibiotics:**
- **Give before LP** if LP delayed (CT needed)
- **Every hour delay = ↑mortality**

### **Duration:**
- ***S. pneumoniae*, *N. meningitidis*, *H. influenzae*:** 7-14 days
- ***Listeria*:** ≥21 days
- **Gram-negative rods:** 21 days

### ***Listeria* Risk:**
- **Age >50, immunocompromised** (transplant, steroids, malignancy)
- **Ceftriaxone does NOT cover *Listeria*** → add ampicillin

### **Clinical Pearls:**
- **Empiric:** Ceftriaxone + vancomycin (+ ampicillin if >50y/immunocompromised)
- **Dexamethasone 10mg IV q6h × 4 days** (with/before antibiotics)
- **Do NOT delay antibiotics** for LP/CT
- **Chemoprophylaxis:** Rifampin/cipro for *N. meningitidis* close contacts
- **Hearing loss:** Common sequela (10-30%, especially *S. pneumoniae*)

## Sources

- [IDSA: Bacterial Meningitis Guidelines 2024]
- [Lancet: Acute Bacterial Meningitis 2024]

## Media

N/A
